DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2022 Earnings Call Transcript

Rick Pauls: Sure. So there’s two doses. So the first is the IV dose that’s being tested in the Phase 1C. So maybe just step back for a moment. So when a patient has a stroke, they come into the hospital and they will get the IV dose of DM199. So in our Phase 1C, we’re planning three initial doses of 0.1, 0.25 and 0.5 micrograms per kg. We believe the 0.5 will be the dose that we’re using based upon the In-Use data, the IV bag study and our previous work. And then that’s followed then clinically with subcu dosing and that’s at 3 micrograms per kg and there’s no change in that. So the subcu dosing occurs twice a week for three weeks and then that will be at 3 micrograms and there’s no impact on that dosing with this hold.

Daniel Hultberg: Great. That makes sense. Thanks for taking my questions.

Rick Pauls: Thank you, Dan.

Operator: Thank you. And we have no further questions in queue. I’ll turn the call back over to our host.

Rick Pauls: All right. Again, we’d like to thank everyone for joining us this morning and for your continued support. The goal of bringing this important treatment to stroke patients as quickly as possible. We appreciate your interest in DiaMedica and your continued support. And this concludes our call today. Thank you.

Operator: That concludes today’s conference call. Thank you for joining and have a pleasant day.